Mini Review
IgA Antibodies: The Mucosal Guardians of Human Immunity
*Corresponding Author: Rinehart E, Institute for Research in Molecular Medicine, Iran
Copyright: ©2026 Rinehart E this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.
Citation: Rinehart E, IgA Antibodies: The Mucosal Guardians of Human Immunity V2(2), 2026
Received: Jul 06, 2026
Accepted: Jul 23, 2026
Published: Jul 29, 2026
Keywords: immunoglobulin a, iga, secretory iga, mucosal immunity, antibodies, immune defense, microbiome, iga deficiency
Abstract
Immunoglobulin A (IgA) is a specialized class of antibody that serves as one of the principal protective barriers between the human body and the external environment. Unlike antibodies that predominantly operate within the bloodstream, IgA is highly concentrated at mucosal surfaces lining the respiratory, gastrointestinal, and genitourinary tracts, as well as in secretions such as saliva, tears, breast milk, and intestinal fluids. Its distinctive ability to neutralize pathogens while limiting unnecessary inflammation makes it particularly important for maintaining mucosal health. IgA exists mainly in two forms: serum IgA, which circulates in the blood, and secretory IgA (sIgA), which is transported across epithelial cells into mucosal secretions. Secretory IgA can bind microorganisms, toxins, and antigens and prevent their attachment and penetration without producing extensive tissue-damaging inflammatory responses. Beyond pathogen defense, IgA contributes to the regulation of the intestinal microbiome and the development of immune tolerance to harmless environmental and dietary antigens. Abnormal IgA production or function has been associated with several conditions, including selective IgA deficiency, IgA nephropathy, certain autoimmune disorders, and mucosal infections. Understanding IgA therefore provides important insights into the relationship between antibody-mediated immunity, epithelial barriers, and the human microbiome. This article reviews the structure, production, functions, clinical significance, and therapeutic relevance of IgA antibodies.
Introduction
The immune system must continuously distinguish between harmful organisms and the enormous number of harmless substances encountered every day. This challenge is particularly significant at mucosal surfaces, where the body comes into direct contact with food, microorganisms, airborne particles, and environmental antigens.
Immunoglobulin A, commonly abbreviated as IgA, is an antibody specifically adapted to this environment. It is the predominant immunoglobulin class found in many mucosal secretions and represents a major component of the body's first-line immune defense.
IgA does not simply destroy microorganisms. Instead, it frequently prevents them from attaching to epithelial surfaces, neutralizes toxins and viruses, and helps control interactions between microorganisms and the mucosal immune system. This protective strategy allows IgA to provide effective defense while minimizing excessive inflammation.
Structure of IgA
Like other immunoglobulins, IgA is composed of heavy and light polypeptide chains. Its basic antibody structure contains two antigen-binding regions that recognize specific molecular targets.
IgA occurs primarily in two structural forms:
Monomeric IgA
Monomeric IgA consists of a single antibody unit and is the predominant form found in the circulation. It is produced mainly by plasma cells located in lymphoid tissues and bone marrow.
Dimeric IgA
At mucosal sites, IgA is commonly produced as a dimer, consisting of two IgA molecules linked by a J (joining) chain. This dimeric form interacts with the polymeric immunoglobulin receptor on epithelial cells.
During transport through epithelial cells, part of this receptor becomes associated with IgA and forms the secretory component. The resulting molecule is known as secretory IgA (sIgA).
This secretory component helps protect IgA from enzymatic degradation in mucosal secretions.
Production of IgA
IgA production is closely associated with mucosal immune tissues. Specialized immune cells stimulate B lymphocytes to undergo class-switch recombination, allowing them to produce IgA instead of other antibody classes.
IgA-producing plasma cells are abundant in tissues associated with the gastrointestinal and respiratory systems.
A simplified pathway can be described as:
Antigen exposure → B-cell activation → class switching to IgA → plasma-cell differentiation → IgA secretion → mucosal protection
The local environment of mucosal tissues plays an important role in regulating IgA production.
IgA and the Gut Microbiome
The human gastrointestinal tract contains a complex community of microorganisms collectively known as the gut microbiome. These microorganisms participate in digestion, metabolism, immune development, and protection against invading pathogens.
IgA contributes to the regulation of this microbial ecosystem by binding selected microorganisms and microbial antigens.
IgA in Breast Milk
Breast milk contains substantial amounts of secretory IgA, particularly during the early period of lactation.
Maternal IgA can provide passive immune protection to the infant's gastrointestinal tract. Because an infant's immune system is still developing, antibodies present in breast milk can help protect mucosal surfaces from potentially harmful microorganisms.
Importantly, secretory IgA functions primarily at mucosal surfaces rather than producing systemic immunity in the same manner as circulating antibodies.
IgA and Respiratory Defense
The respiratory tract is continuously exposed to airborne particles, viruses, and bacteria. Secretory IgA present in respiratory secretions contributes to defense by binding inhaled pathogens and interfering with their ability to attach to respiratory epithelial cells.
This mucosal defense system is particularly important because respiratory pathogens can encounter the body before systemic immune responses have been activated.
IgA therefore represents an important component of early respiratory immune protection.
Future Perspectives
Research into IgA is increasingly focused on the relationship between mucosal immunity, microbiome composition, vaccination, and chronic disease.
Future studies may improve understanding of how IgA recognizes specific microorganisms and how these interactions influence health and disease.
Conclusion
IgA is a fundamental component of human mucosal immunity. Its concentration at epithelial surfaces allows the immune system to confront microorganisms at their points of entry while maintaining a relatively controlled inflammatory environment.
Through neutralization, prevention of microbial attachment, immune exclusion, and regulation of the microbiome, IgA performs functions that extend beyond conventional antibody-mediated pathogen destruction.
Both insufficient and abnormal IgA responses can have clinical consequences, demonstrating the importance of maintaining appropriate mucosal immune regulation. Continued research into IgA biology may contribute to improved diagnostic methods, mucosal vaccines, and antibody-based therapies.
References
-
Zanini, B.; Marullo, M.; Villanacci, V.; Salemme, M.; Lanzarotto, F.; Ricci, C.; Lanzini, A. Persistent Intraepithelial Lymphocytosis in Celiac Patients Adhering to Gluten-Free Diet Is Not Abolished Despite a Gluten Contamination Elimination Diet. Nutrients 2016, 8, 525.
-
Porcelli, B.; Ferretti, F.; Biviano, I.; Santini, A.; Cinci, F.; Vascotto, M.; Grande, E.; Quagliarella, F.; Terzuoli, L.; Bizzaro, N.; et al. Testing for fecal gluten immunogenic peptides: A useful tool to evaluate compliance with gluten-free diet by celiacs. Ann. Gastroenterol. 2020, 33, 631–637.
-
Garnier, M.; Chang, C.J.; Zreik, L.; Rossetti, V.; Bové, J.M. Citrus variegated chlorosis: Serological detection of Xylellafastidiosa, the bacterium associated with the disease. Int. Organ. Citrus Virol.Conf. Proc. (1957–2010) 1993, 12, 301–305.
-
Minsavage, G.V.; Thompson, C.M.; Hopkins, D.L.; Leite, R.M.V.B.C.; Stall, R.E. Development of a polymerase chain reaction protocol for detection of Xylellafastidiosa in plant tissue. Phytopathology 1994, 84, 456–461.
-
Hilton, A.; Wang, X.; Zhang, M.; Cervantes, K.; French, J.; Randall, J.J.; Bock, C.H.; Grauke, L.J.; Jo, Y. Improved methods for detecting Xylella fastidiosa in pecan and related Carya species. Eur. J. Plant Pathol. 2020, 157, 899–918.
-
Chen, T.; Hedman, L.; Mattila, P.S.; Jartti, L.; Jartti, T.; Ruuskanen, O.; Söderlund-Venermo, M.; Hedman, K. Biotin IgM antibodies in human blood: A previously unknown factor eliciting false results in biotinylation-based immunoassays. PLoS ONE 2012, 7, e42376.
-
Matlach, J.; Bender, S.; Konig, J.; Binder, H.; Pfeiffer, N.; Hoffmann, E.M. Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression. Clin. Ophthalmol. 2019, 13, 9–16.
